Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data

Wu, Eric Q.; Chen, Lei; Birnbaum, Howard G.; Yang, Elaine; Cifaldi, M.

doi:10.1185/030079907x210615

Cited by 34 publications

(35 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a study of the USA population showed similar data (10). The two papers showed that the annual healthcare cost was significantly less than for infliximab patients.…”

Section: Discussionsupporting

confidence: 56%

The Economic Burden of Biological Therapy in Rheumatoid Arthritis in Clinical Practice: Cost-Effectiveness Analysis of Sub-Cutaneous Anti-TNFα Treatment in Italian Patients

Benucci

Gobbi

Sabadini

et al. 2009

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Rheumatoid arthritis (RA), with a prevalence of 0.46%, is found in about 272,004 patients in Italy. The socioeconomic cost of rheumatoid arthritis in Italy in 2002 has been estimated at Euro 1,600 million. Cost-effectiveness evaluations have been based on the concept that, with treatment, patients will not progress to the next level(s) of disease severity or will take a longer time to progress, thus avoiding or delaying the high costs and low utility associated with more severe disease. Many cost-effective studies have been based on the variation of Health Assessment Questionnaire (HAQ) in clinical trials. The objective of this study is to perform a cost-effective analysis of 86 patients with rheumatoid arthritis in therapy with adalimumab 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice. The group of patients in therapy with adalimumab had also taken methotrexate, mean dose 12.4+/-2.5 mg/week (22 patients) or leflunomide 20 mg/day (16 patients). The group of patients in therapy with etanercept had also taken methotrexate, mean dose 11.7+/-2.6 mg/week (24 patients) or leflunomide 20 mg/day (24 patients). Incremental costs and QALYs (quality adjusted life years) gains are calculated compared with baseline, assuming that without biologic treatment patients would remain at the baseline level through the year. Conversion HAQ scores to utility were based on the Bansback algorithm. The results after two years showed: in the group methotrexate+adalimumab the QALY gained was 0.62+/-0.15 with a treatment cost of Euro 26,517.62 and a QALY/cost of Euro 42,521.13. In the group methotrexate + etanercept the QALY gained was 0.64+/-0.26 with a treatment cost of Euro 25,020.96 and a QALY/cost of Euro 39,171.76. The result of using etanercept in association with methotrexate is cost-effectiveness with a QALY gained under the acceptable threshold of Euro 50,000. These are important data for discussion from an economic point of view when we choose a biologic therapy for rheumatoid arthritis in clinical practice.

show abstract

“…In addition, a study of the USA population showed similar data (10). The two papers showed that the annual healthcare cost was significantly less than for infliximab patients.…”

Section: Discussionsupporting

confidence: 56%

The Economic Burden of Biological Therapy in Rheumatoid Arthritis in Clinical Practice: Cost-Effectiveness Analysis of Sub-Cutaneous Anti-TNFα Treatment in Italian Patients

Benucci

Gobbi

Sabadini

et al. 2009

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…Thus, this analysis complements previous analyses that also reported that the cost of etanercept was the lowest of the TNF blockers among patients with rheumatoid arthritis. [17][18][19][20][21] In this analysis, estimates of total annual costs of TNFblocker treatment included the costs of both the index TNF blocker and the nonindex TNF blockers among patients who switched treatment in the first year after the index date. The intent was to provide a real-world estimate of the total annual cost of TNF-blocker treatment.…”

Section: Limitationsmentioning

confidence: 99%

Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population

Schabert¹,

Watson²,

Joseph³

et al. 2013

JMCP

View full text Add to dashboard Cite

BACKGROUND: Several anti-inflammatory biologic medications are available in the United States for the treatment of moderate-to-severe rheumatoid arthritis, moderate-to-severe psoriasis, psoriatic arthritis, or ankylosing spondylitis. The tumor necrosis factor (TNF) blockers etanercept, adalimumab, and infliximab are approved for use in adults with any of these conditions, but predicting the annual costs of TNF-blocker treatment is complex due to differences in dosing schedules, treatment gaps, switching between TNF blockers, and dose escalation over time.

show abstract

“…Wu and colleagues conducted a national database study to compare the cost of care with adalimumab, infliximab and etanercept for 1 year (beginning 1 January 2003) in privately insured patients with RA [79]. Healthcare utilization and costs were assessed for both non-RA-and RA-related medical costs.…”

Section: Cost-of-care Studiesmentioning

confidence: 99%

Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease

Gladman¹,

Brown²

2008

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, prevents disease progression in some patients and, in the case of Crohn's disease, induces and maintains remission. Compared with traditional disease-modifying antirheumatic drugs that offer significantly less benefit, adalimumab is much more costly. However, most studies to date demonstrate the cost-effectiveness of adalimumab treatment. Cost-effectiveness data for newer indications of adalimumab, including ankylosing spondylitis and Crohn's disease, are needed. As longer term data for adalimumab become available, the cost-effectiveness data will have greater precision.

show abstract

Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data

Cited by 34 publications

References 7 publications

The Economic Burden of Biological Therapy in Rheumatoid Arthritis in Clinical Practice: Cost-Effectiveness Analysis of Sub-Cutaneous Anti-TNFα Treatment in Italian Patients

The Economic Burden of Biological Therapy in Rheumatoid Arthritis in Clinical Practice: Cost-Effectiveness Analysis of Sub-Cutaneous Anti-TNFα Treatment in Italian Patients

Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population

Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease

Contact Info

Product

Resources

About